Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter
Access to hospital-based eye care and reimbursement were policy topics at the…
Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome…
Two transactions announced in September and October 2026 show capital moving through…
GenSight Biologics and the Quinze-Vingts National Ophthalmology Hospital in Paris announced on…
This segment examines how the advent of higher-dose and dual-pathway anti-VEGF agents…
(Image Credit: AdobeStock/Sangiao_Photography) Pterygium is a common ocular surface disorder characterized by…
(Image Credit: AdobeStock/SnapVault) Argenx SE has discontinued the phase 3 UplighTED studies…
(Image Credit: AdobeStock/9dreamstudio) Aviceda Therapeutics has released topline results from its phase…
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained…
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained…
(Image Credit: AdobeStock) Inflammasome Therapeutics has completed enrollment in a multicenter phase…
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine…
Presbyopia-correcting IOLs have undergone a dramatic transformation in recent years. The once-limited…
Enter your email address below and subscribe to our newsletter